Crinetics Pharmaceuticals (CRNX) Amortization of Deferred Charges (2024 - 2026)

Crinetics Pharmaceuticals' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $703000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 13.53% year-over-year to $703000.0 in Q1 2026; TTM through Mar 2026 was $2.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.0 million, down 0.92% from the prior year.
• Amortization of Deferred Charges advanced to $703000.0 in Q1 2026 per CRNX's latest filing, from $654000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $813000.0 in Q1 2025 and bottomed at $654000.0 in Q4 2025.
• The 3-year median for Amortization of Deferred Charges is $731000.0 (2024), against an average of $732250.0.
• Across the five-year window, Amortization of Deferred Charges retreated 13.83% in 2025 and fell 13.53% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $759000.0 in 2024, then dropped by 13.83% to $654000.0 in 2025, then rose by 7.49% to $703000.0 in 2026.
• Per Business Quant, the three latest CRNX Amortization of Deferred Charges figures stand at $703000.0 (Q1 2026), $654000.0 (Q4 2025), and $813000.0 (Q1 2025).